LRRC32/GARP Antibody (725226) [Alexa Fluor™ Plus 647]

• Reactivity: Mu
• Clone: 725226
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor Plus 647

LRRC32/GARP Antibody (725226) [Alexa Fluor™ Plus 647] Summary

• Specificity: Detects mouse LRRC32/GARP in direct ELISAs. In direct ELISAs, approximately 50% cross-reactivity with recombinant human (rh) LRRC32 is observed and no cross-reactivity with rhLRRC3, rhLRRC4, or rhNGL-3/LRRC4B is observed.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Rat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for LRRC32/GARP Antibody (725226) [Alexa Fluor™ Plus 647]

• D11S833E
• D11S833Eleucine-rich repeat-containing protein 32
• GARP
• GARPGarpin
• Garpin
• Glycoprotein A repetitions predominantgarpin
• leucine rich repeat containing 32
• LRRC32

Background

Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant), is an 80 kDa type I transmembrane glycoprotein (1). Mature mouse LRRC32 consists of a 608 amino acid (aa) extracellular domain (ECD) that contains 22 leucine-rich repeats, a 21 aa transmembrane segment, and a 14 aa cytoplasmic domain (2-4). Within the ECD, mouse LRRC32 shares 80 and 94% aa sequence identity with human and rat LRRC32, respectively. LRRC32 is widely expressed during embryogenesis and on adult platelets (4, 5). Among T cells, it is selectively expressed on activated FOXP3+ regulatory T cells (Treg) (6-10). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells (6-8). LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells (9, 10). The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation (11).

1. Battaglia, M. and M.G. Roncarolo (2009) Eur. J. Immunol. 39:3296.
2. Ollendorff, V. et al. (1994) Cell Growth Differ. 5:213.
3. Bella, J. et al. (2008) Cell Mol Life Sci. 65:2307.
4. Roubin, R. et al. (1996) Int. J. Dev. Biol. 40:545.
5. Macaulay, I.C. et al. (2007) Blood 109:3260.
6. Wang, R. et al. (2008) PloS ONE 3:e2705.
7. Wang, R. et al. (2009) Proc. Natl. Acad. Sci. 106:13439.
8. Probst-Kepper, M. et al. (2009) J. Cell. Mol. Med. 13:3343.
9. Tran, D.Q. et al. (2009) Proc. Natl. Acad. Sci. 106:13445.
10. Stockis, J. et al. (2009) Eur. J. Immunol. 39:3315.
11. Vignali, D.A. et al. (2008) Nat. Rev. Immunol. 8:523.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.